Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
| Autor: | Belén Gómez-Carrillo, Teresa Leon, David Fleet, María V. Andrés, Pilar Redondo, Klaus C. Steinwachs, Miguel Medina, Hermann Josef Gertz, Teodoro Del Ser, Joan A. Vericat |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Pilot Projects Placebo Asymptomatic Glycogen Synthase Kinase 3 Double-Blind Method Alzheimer Disease Internal medicine Statistical significance Thiadiazoles medicine Humans Adverse effect Protein Kinase Inhibitors Aged Cholinesterase Aged 80 and over biology business.industry General Neuroscience General Medicine Middle Aged Clinical trial Psychiatry and Mental health Clinical Psychology Treatment Outcome Tolerability Physical therapy biology.protein Drug Therapy Combination Female Geriatric Depression Scale Cholinesterase Inhibitors Geriatrics and Gerontology medicine.symptom business |
| Zdroj: | Journal of Alzheimer's Disease. 33:205-215 |
| ISSN: | 1875-8908 1387-2877 |
| Popis: | This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer's disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, and 6 weeks, respectively. The primary objective was to evaluate the safety and tolerability of tideglusib with strict criteria for drug escalation or withdrawal. Mini-Mental Status Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog+), word fluency, Geriatric Depression Scale (GDS), and a final Global Clinical Assessment (GCA) were assessed as secondary objectives. Treatment was well tolerated. Adverse events were as frequent in active and placebo groups, except for some moderate, asymptomatic, and fully reversible increases (>2.5 × ULN) of serum transaminases in 6 active cases (p = 0.001). Tideglusib produced positive trends in MMSE, ADAS-cog, GDS, and GCA without statistical significance in this small sample. Responders in MMSE were significantly higher in the active group (p = 0.05). Patients escalated up to 1000 mg/day had a benefit of 1.68 points in the MMSE and 4.72 points in the ADAS-cog+ when compared to placebo. This small pilot study provides valuable safety and efficacy estimates for the treatment of AD patients with tideglusib, currently being confirmed in a larger clinical trial. Due to escalating doses and the small sample size, this trial provides insufficient evidence to support or reject a benefit of tideglusib in AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|